KarXT shows preliminary symptom improvements in Phase III Alzheimer’s psychosis studies

Bristol Myers Squibb has reported the first clinical data from its Phase III ADEPT programme evaluating KarXT in patients with psychosis associated with Alzheimer’s disease.

Preliminary findings from the open-label portions of the ADEPT-1 and ADEPT-3 studies showed reductions in hallucination and delusion scores alongside improvements in overall disease severity.

The results were presented at the Clinical Trials on Alzheimer’s Disease Conference.

The ADEPT studies remain ongoing, and data from the double-blind treatment periods are still blinded.

The findings reported so far are based on descriptive analyses and do not include placebo-controlled efficacy comparisons.

In ADEPT-1, 320 participants had enrolled at the time of analysis and 273, or 85.3%, completed the 12-week open-label lead-in period.

Among evaluable patients, treatment with KarXT was associated with a mean 12.0-point reduction from a baseline score of 14.4 on the Neuropsychiatric Inventory-Clinician Hallucinations and Delusions scale.

A mean 1.9-point improvement from a baseline score of 4.5 was also observed on the Clinical Global Impression-Severity scale.

Treatment-emergent adverse events occurred in 56.6% of participants during the ADEPT-1 open-label period.

Serious treatment-emergent adverse events were reported in 5.0%, while 4.4% discontinued treatment because of an adverse event.

The Phase III ADEPT-3 study is a 52-week open-label extension for patients completing ADEPT-1, ADEPT-2 or ADEPT-4.

Among 401 participants enrolled at the time of analysis, 273, or 68.1%, completed the 52-week treatment period.

Patients recorded a mean 5.1-point reduction from an open-label baseline score of 8.9 on the NPI-C hallucinations and delusions scale.

The Clinical Global Impression-Severity score decreased by an average of 0.8 points from a baseline of 3.4.

KarXT was generally well tolerated through one year.

Treatment-emergent adverse events occurred in 65.1% of participants, serious events in 7.7%, and events leading to treatment discontinuation in 4.7%.

No new safety signals were identified.

Jeffrey Cummings, MD, ScD, Director of the Chambers-Grundy Center for Transformative Neuroscience at the University of Nevada, Las Vegas, said the findings provide an initial look at how KarXT may affect hallucinations and delusions in patients with Alzheimer’s disease.

Cristian Massacesi, MD, Executive Vice President, Chief Medical Officer and Head of Development at Bristol Myers Squibb, said ADEPT-1 and ADEPT-3 are designed to address different questions, with ADEPT-1 assessing initial response and ADEPT-3 focusing on longer-term safety and tolerability.

The broader ADEPT programme includes placebo-controlled Phase III studies assessing acute efficacy as well as relapse prevention and alternative dosing strategies.

ADEPT-1 includes a 12-week open-label treatment period followed by a 26-week double-blind randomised withdrawal phase, with time to relapse as the primary endpoint.

ADEPT-3 is evaluating the long-term safety and tolerability of KarXT over 52 weeks.

KarXT combines xanomeline, a muscarinic M1- and M4-preferring receptor agonist, with trospium chloride, a peripheral muscarinic receptor antagonist intended to reduce cholinergic side effects.

The combination is already approved in the U.S. under the brand name Cobenfy for adults with schizophrenia.

Bristol Myers Squibb is also developing KarXT across additional neurological and psychiatric conditions, including Alzheimer’s disease-related agitation and cognitive impairment, bipolar I disorder and autism-associated irritability.



Related Topics and Keywords

, , , , , , , , , , , , , , , , , , , , , ,

Subscribe to our FREE newsletter and WEBINAR UPDATES

We will not sell or give your information to a third party. See our Privacy Policy